Our mission is to develop novel targeted anti-cancer therapies to improve patient outcomes and quality-of-life. This approach is based on a comprehensive understanding of the molecular interactions and pathways that promote cancer pathology and how those can be manipulated to elicit therapeutic response. To achieve this, we design and investigate small molecule nuclear receptor inhibitors to reprogram transcription, prevent metastasis, and shrink tumors. We are active and engaged members of the global scientific community. We are committed to an open, rigorous, empirical, and reproducible approach to improving lives.